Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — Technical Presentation (April 2026)
12 slides from Aldeyra Therapeutics's technical presentation, Apr 10, 2026
Slide 1: Reproxalap Acutely Reduces Ocular Discomfort in Phase 3 Dry Eye Disease Chamber Trial
Reproxalap Acutely Reduces Ocular Discomfort Title of3 Presentation, in Phase TitleChamber Dry Eye Disease Case Trial Eric Donnenfeld, MD;1 Desiree Owen, OD;2 Ashley Nguyen, PharmD;2 Todd Brady, MD, PhD3 1Opthalmic Consultants of Long Island, Garden City, NY, USA; 2Allergan, an AbbVie company, North
Slide 2: Acknowledgments, funding and disclosures
Aldeyra Therapeutics, AbbVie Inc., and the authors thank the participants, study sites, and investigators who participated in this clinical trial. Aldeyra Therapeutics funded this trial and participated in the trial design, research, data collection, analysis, interpretation of data, and review and
Slide 3: Introduction
Introduction Objective: This Phase 3 trial assessed patient-reported ocular discomfort using a visual analog scale (0-100) following treatment with either 0.25% reproxalap or vehicle to determine improvements in ocular discomfort in patients with dry eye disease (DED) DED is a common ocular conditio
Slide 4: Methods
Methods Trial Design: Single-center, randomized, double-masked, vehicle-controlled, parallel group, Phase 3 clinical trial that was conducted in a dry eye chamber and included 3 visits Visit 1: Screening/ Vehicle Chamber Visit Visit 2: Randomization • Medical screening and administration of vehicle
Slide 5: Figure 1. Patient Disposition
Figure 1. Patient Disposition Randomized N = 116 Reproxalap Vehicle (n = 58) (n = 58) Discontinued (n = 1) Scheduling conflict, n = 1 Completed Completed (n = 57) (n = 58)
Slide 6: Baseline characteristics were similar for both groups
Baseline characteristics were similar for both groups Table 1. Baseline Characteristics Reproxalap Vehicle Outcome n = 58 n = 58 Age, mean (SD) 63.1 (12.6) 65.5 (10.9) Age ≥ 65, n (%) 30 (51.7) 32 (55.2) Female, n (%) 42 (72.4) 36 (62.1) Ethnicity, n (%) Hispanic or Latino 4 (6.9) 1 (1.7) Not Hispan
Slide 7: Reproxalap-treated patients experienced significantly less ocular discomfort
Reproxalap-treated patients experienced significantly less ocular discomfort Table 2. Primary Efficacy Analysis: Ocular Discomfort Symptom Score (ITT Population Observed Data Only) Reproxalap Vehicle Outcome n = 58 n = 58 Overall change from Vehicle Chamber to Treatment Chamber (80 to 100 minutes) L
Slide 8: Ocular discomfort remained lower in reproxalap-treated patients for the entirety of the chamber
Ocular discomfort remained lower in reproxalap-treated patients for the entirety of the chamber Figure 2. Ocular Discomfort Score by Treatment and Chamber (ITT Population) • Scores at the beginning of the Treatment Chamber (0 to 50 minutes) were not notably different across treatment groups because
Slide 9: Ocular discomfort scores were lower for a greater proportion of reproxalap-treated patients
Ocular discomfort scores were lower for a greater proportion of reproxalap-treated patients Figure 3. Distribution Function of Change From Baseline in Ocular Discomfort Dry Eye Chamber Score (Treatment Chamber - Vehicle Chamber) Averaged Across Eyes and Primary Endpoint Contrast Timepoints (80 to 10
Slide 10: Most ocular TEAEs were mild or moderate for reproxalap-treated patients
Most ocular TEAEs were mild or moderate for reproxalap-treated patients Table 3. All Treatment and Ocular Treatment-Emergent Adverse Events (Safety Population) Reproxalap Vehicle • 41 (70.7%) of patients in the reproxalap group TEAEs n = 58 n = 58 experienced ≥ 1 TEAE compared with 2 (3.4%) of n (%)
Slide 11: Limitations
Limitations • Interpretation of this study is limited by several factors including: Single-center design Small number of patients included Long-term effects not assessed
Slide 12: Conclusions
Conclusions Patient-reported ocular discomfort scores from Vehicle Chamber to Treatment Chamber for 80 to 100 minutes after dry eye chamber entry were significantly lower in reproxalap-treated patients compared with vehicle-treated patients The primary endpoint of ocular discomfort symptom score was
Aldeyra Therapeutics — Technical Presentation (April 2026) on 6ix